ABSTRACT:
Rilpivirine is used to treat human immunodeficiency virus type 1 (HIV-1). A new stability indicating RP-UPLC method has been developed for the estimation of Rilpivirine and N-Oxide impurity using Waters UPLC Aqcuity SYSTEM with TUV detector integrated with Empower 2 Software with Kromasil (250 × 4.6 mm, 5µm) C18 column (PDA detector) was used for the present study. A mixture of 0.1% ortho phosphoric acid solution and methanol (50: 50, v/v) was used as the mobile phase for the chromatographic study (Flow rate: 1.0 ml/min; Detection wavelength: 279 nm). Stress degradation studies were performed and the method was validated as per ICH guidelines.
Cite this article:
Varada Soujanya, Revu Baby Nalanda. Analytical method development and validation for the estimation of Rilpivirine and its N-Oxide impurity using UPLC. Research Journal of Pharmacy and Technology. 2023; 16(12):6110-6. doi: 10.52711/0974-360X.2023.00992
Cite(Electronic):
Varada Soujanya, Revu Baby Nalanda. Analytical method development and validation for the estimation of Rilpivirine and its N-Oxide impurity using UPLC. Research Journal of Pharmacy and Technology. 2023; 16(12):6110-6. doi: 10.52711/0974-360X.2023.00992 Available on: https://rjptonline.org/AbstractView.aspx?PID=2023-16-12-93
REFERENCES:
1. Weiss J and Haefeli WE. Potential of the novel antiretroviral drug Rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro. Int J Antimicrob Agents. 2013; 41(5): 484-487.
2. Ajay Gupta, Swati Guttikar, Yogesh Patel, Pranav SS and Mallika Sanyal. Reliable LC-MS/MS assay for the estimation of Rilpivirine in human plasma: Application to a bioequivalence study and incurred sample reanalysis. Drug Test Anal. 2015; 7(4): 290-299.
3. Chilukuri M, Hussain K R, Narayanareddy P, Venkataramana M. Degradation Pathway for Rilpinavir Hydrochloride by Validated Stability Indicating UP-LC Method. Int J Clin Pharmacol Toxicol. 2012; 1(1): 1-8.
4. Shibata M, Takahashi M, Yoshino M, Kuwahara T, Nomura T, Yokomaku Y, Sugiura W Development and application of a simple LC-MS method for the determination of plasma Rilpivirine (TMC-278) concentrations. J Med Invest. 2013; 60(1-2): 35-40.
5. Raju AV and Appala Raju N. Development and validation of a LC-MS/MS method for the determination of Rilpivirine in sprague dawley rat serum and its application to pharmacokinetic study. Asian Journal of Biomedical and Pharmaceutical Sciences. 2013; 3(21): 23-29.
6. Laxminarayana B, Pilli NR, Makula A, Lodagala DS, Kandhagatla R. Liquid chromatography‐tandem mass spectrometric assay for the non‐nucleoside reverse transcriptase inhibitor Rilpivirine in human plasma. Biomed Chromatography. 2013; 27(2): 172-178.
7. Priyanka Vallabh Deulkar, Mukthinuthalapati Mathrusri Annapurna. A new stability indicating RP-UFLC method for the estimation of Rilpivirine in pharmaceutical dosage forms. Research J. Pharm. and Tech. 2023; 16(7): 3456-3462.
8. Abhijit AD, Shibata A, Bruck P, Destache CJ. Development and validation of a simple and isocratic reversed-phase HPLC method for the determination of Rilpivirine from tablets, nanoparticles and HeLa cell lysates. Biomed Chromatography. 2015; 29(5): 709-715.
9. Rubesh Kumar, Uma Maheshwar Rao V, Ramakanth K, Adharsh K, Prashanth K, Qadeer MA, Shravya M. RP-HPLC method development and validation of Rilpivirine pharmaceutical dosage form. International Journal of Pharmacy and Analytical Research. 2019; 8(3): 329-337.
10. Kumar BMS, Rajkamal B and Chandramowli B. Development and Validation of Rilpivirine in Pharmaceutical Formulation by RP-HPLC. American Journal of PharmTech Research 2019; 9(3): 344-353.
11. Somsubhra Ghosh, Sowjanya B, Laxmi P.V, Vidyadhar S, David B, Subhadip R. Method development and validation of Rilpivirine in bulk and tablet doses form by RP-HPLC method. Research J Pharm and Tech. 2013; 6(3): 240-243.
12. Raj Kumar B and Subrahmanyam KV. A Validated Stability-Indicating RP-HPLC method for the determination of Rilpivirine. Journal of Global Trends in Pharmaceutical Sciences. 2014; 5(3): 1822-1826.
13. Yasodha A, Rani J, Venkataih G, Sivakumar A. RP-HPLC method development and validation of Rilpivirine. Int. J. of Pharmacy and Analytical Research. 2017; 6(1): 18-38.
14. Sudha T, Shanmugasundram P. Reverse phase high performance and HPTLC methods for the determination of rilpivirine bulk and in tablet dosage form. World J Pharm Res. 2012; 1(4): 1183-1196.
15. ICH Validation of Analytical Procedures: Text and Methodology Q2 (R1), International Conference on Harmonization. 2005.
16. ICH Stability Testing of New Drug Substances and Products Q1A (R2), International Conference on Harmonization. 2003.
17. ICH Q3A (R2) Impurities of New Drug Substances. 2006.